This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schlom, J. Articles by Groupé, V. Search for Related Content PubMed PubMed Citation Articles by Schlom, J. Articles by Groupé, V.

Immunological and Pathological Manifestations of Murine Sarcoma Virus (Moloney) Infections¹

Institute of Microbiology, Rutgers University, New Brunswick, New Jersey 08903 [J. S., V. G.], and Viral Leukemia and Lymphoma Branch, National Cancer Institute, NIH, Bethesda, Maryland 20014 [J. B. M.]

Mice were immunized against Moloney sarcoma virus (MSV) challenge by the serial inoculation of increasing doses of live MSV preparations. Only 15% of vaccinated mice developed tumors after challenge with a dose of MSV sufficient to cause tumors in 100% of control mice. This resistance was not accompanied by detectable levels of MSV-neutralizing antibody. Adult mice susceptible to MSV tumor induction displayed antibody levels following tumor regression that were sufficient to neutralize greater than 10^3.2 median effective doses of MSV. Antibody titers were independent of initial MSV dose but were directly related to tumor duration.

The pathogenesis of MSV-induced tumors in weanling and adult mice was characterized by spontaneous regression of tumors (rhabdomyosarcomas) followed by a relapse phase. Onset of relapse was correlated with architectural changes in the mesenchymal region surrounding splenic follicles. This was followed by the appearance of metastatic lesions in various organs and subsequent death.

¹ This investigation was supported in part by USPHS Training Grant CA-05175.

² Portions of the data were submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy, Rutgers University. Present address: Institute of Cancer Research, College of Physicians and Surgeons of Columbia University, New York, N. Y. 10032.

³ Chief, Viral Leukemia and Lymphoma Branch, National Cancer Institute, Bethesda, Md. 20014, and Visiting Investigator, Institute of Microbiology, Rutgers University, New Brunswick, N. J. 08903.

⁴ Present address: Life Sciences, Inc., 2900 72nd Street North, St. Petersburg, Fla. 33710.

Received 5/22/70. Accepted 9/10/70.